ARTICLE | Clinical News
ATL-104 recombinant protein: AZM will start this quarter a German Phase Ib trial of ATL-104 dosed for 5 days in 36 healthy volunteers.
January 22, 2002 8:00 AM UTC
Alizyme plc (LSE:AZM), Cambridge, U.K. Product: ATL-104 recombinant protein Business: Cancer Therapeutic category: Cell proliferation Target: NA Description: Recombinant plant lectin protein that stim...